Market Place
Sourcing Support
Connect Bio To Present At Leerink Partners Global Healthcare Conf
03 Mar 2026 //
GLOBENEWSWIRE
Connect Bio To Present At 8Th Evercore Healthcare Conference
24 Nov 2025 //
GLOBENEWSWIRE
Connect Bio Reports Q3 2025 Financials & Business Update
12 Nov 2025 //
GLOBENEWSWIRE
Connect Bio Presents Rademikibart Data At ERS Congress 2025
29 Sep 2025 //
GLOBENEWSWIRE
Connect Biopharma Presents Twice at ERS Congress 2025
04 Sep 2025 //
GLOBENEWSWIRE
Connect Biopharma to Present at Investor Conferences in September
27 Aug 2025 //
GLOBENEWSWIRE
Connect Biopharma`s Q2 2025 Financial Results and Business Update
13 Aug 2025 //
GLOBENEWSWIRE
Industry Veteran Jim Schoeneck Joins Connect Biopharma Board
22 Jul 2025 //
GLOBENEWSWIRE
Connect Bio to End ADR Program, List Ordinary Shares on Nasdaq
21 Jul 2025 //
GLOBENEWSWIRE
Connect Biopharma Complies with Nasdaq`s Minimum Bid Price Rule
17 Jul 2025 //
GLOBENEWSWIRE
Connect Biopharma to Present at EAACI 2025 Annual Congress
03 Jun 2025 //
GLOBENEWSWIRE
Connect Biopharma to Present at Investor Conferences in June
28 May 2025 //
GLOBENEWSWIRE
Connect Biopharma Presents Data on Rademikibart at ATS 2025
20 May 2025 //
GLOBENEWSWIRE
Connect Biopharma Starts COPD Trial of Rademikibart in STAT Study
14 May 2025 //
GLOBENEWSWIRE
Connect Biopharma Starts Phase 2 Asthma Study of Rademikibart
13 May 2025 //
GLOBENEWSWIRE
Connect Biopharma to Present at ATS 2025 Conference
24 Apr 2025 //
GLOBENEWSWIRE
Connect Biopharma Reports 2024 Financials and Business Update
31 Mar 2025 //
GLOBENEWSWIRE
Connect Biopharma gets Nasdaq notice on minimum bid price
28 Mar 2025 //
GLOBENEWSWIRE
Connect Biopharma to Present at Two Upcoming Investor Conferences
03 Mar 2025 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2024 Financial Results
05 Sep 2024 //
GLOBENEWSWIRE
Connect Biopharma To Join Leerink Partners I&I Forum
01 Jul 2024 //
GLOBENEWSWIRE
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12 Jun 2024 //
GLOBENEWSWIRE
Connect Biopharma Announces Inducement Grants Under Nasdaq Rules
12 Jun 2024 //
GLOBENEWSWIRE
Connect Biopharma Asthma Data At ATS 2024
07 May 2024 //
GLOBENEWSWIRE
Connect uncouples from Pfizer by scrapping eczema pact
17 Apr 2024 //
FIERCE BIOTECH
Connect Biopharma Reports 2023 Financials, Provides Business Update
16 Apr 2024 //
GLOBENEWSWIRE
Connect Biopharma to Participate in Virtual Conference
19 Mar 2024 //
GLOBENEWSWIRE
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
13 Feb 2024 //
GLOBENEWSWIRE
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
12 Feb 2024 //
GLOBENEWSWIRE
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
04 Jan 2024 //
PR NEWSWIRE
Connecting the dots: Asthma asset aces phase 2b trial
12 Dec 2023 //
FIERCE BIOTECH
Connect Biopharma and Simcere Announce Agreement in Greater China
21 Nov 2023 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2023 Financial Results
12 Sep 2023 //
GLOBENEWSWIRE
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice
12 Sep 2023 //
GLOBENEWSWIRE
Connect Biopharma to Participate in Upcoming September Investor Conferences
24 Aug 2023 //
GLOBENEWSWIRE
Connect Bio Presented Additional Data from its Atopic Dermatitis Pivotal Trial
10 Jul 2023 //
GLOBENEWSWIRE
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
05 Jul 2023 //
GLOBENEWSWIRE
Connect Biopharma Announces Positive Data from Icanbelimod Trial
01 Jun 2023 //
GLOBENEWSWIRE
Connect Reports Full Year 2022 Financial Results and Provides Business Update
11 Apr 2023 //
GLOBENEWSWIRE
Connect Biopharma to Present at SVB Securities Global Biopharma Conference
06 Feb 2023 //
GLOBENEWSWIRE
Connect Biopharma Provides Business and Clinical Development Program Update
30 Dec 2022 //
GLOBENEWSWIRE
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
19 Dec 2022 //
GLOBENEWSWIRE
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
27 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports CBP-201 Achieved All Primary & Key Secondary Endpoints
04 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports CBP-201 Achieved All Primary & Key Secondary Endpoints
04 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma to Host a Conference Call, Oct 4 to Discuss Topline Results
03 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2022 Financial Results a
13 Sep 2022 //
GLOBENEWSWIRE
Connect Biopharma to Report First Half 2022 Financial Results on September 13
01 Sep 2022 //
GLOBENEWSWIRE
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose
30 Aug 2022 //
GLOBENEWSWIRE
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice
17 Jun 2022 //
GLOBENEWSWIRE
Connect Biopharma to Participate at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data
17 May 2022 //
GLOBENEWSWIRE
Chasing BMS and Pfizer, Connect fails ulcerative colitis trial
05 May 2022 //
FIERCEBIOTECH
Connect Biopharma reports a PII fail for Zeposia challenger
04 May 2022 //
ENDPTS
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial
03 May 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Connect Biopharma Appoints Chin Lee, MD, MPH as Chief Medical Officer
01 Mar 2022 //
GLOBENEWSWIRE
Connect Biopharma Expands Executive Leadership Team with Hire
22 Nov 2021 //
GLOBENEWSWIRE
Connect Bio celebrates mid-stage win for Dupixent rival, but shares tank
20 Nov 2021 //
ENDPTS
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial
19 Nov 2021 //
GLOBENEWSWIRE
